# Hester Biosciences (NSE: HESTERBIO) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/HESTERBIO · Pivot · prices to 21 Oct 2026

Hester Biosciences (NSE: HESTERBIO) closed at ₹2,195.00 on 21 Oct 2026. With a market capitalisation of ₹1,940 Cr, it ranks 1170th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 33.7× trailing earnings, against a return on equity of 8.7% in FY25. Over the past year the share price has risen 31.4%. Its 52-week range is ₹1,239.30 (30 Mar 2026) to ₹2,683.60 (30 Jul 2026); the last close is 18.2% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹77 Cr (−8.2% year on year) and net profit ₹95 Cr (+482.8%), on a consolidated basis. Promoters held 53.73% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹2,195.00 |
| Market cap | ₹1,940 Cr |
| P/E (trailing) | 33.7 |
| ROE | 8.7% (FY25) |
| ROCE | 9.1% (FY25) |
| Debt to equity | 0.66 |
| 52-week high | ₹2,683.60 (30 Jul 2026) |
| 52-week low | ₹1,239.30 (30 Mar 2026) |
| 1-year return | +31.4% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹77 Cr | −8.2% | ₹95 Cr | +482.8% | ₹113.71 |
| Q4 FY26 | ₹100 Cr | +22.2% | ₹15 Cr | +6,287.0% | ₹19.45 |
| Q3 FY26 | ₹77 Cr | +22.5% | ₹8 Cr | −23.3% | ₹10.94 |
| Q2 FY26 | ₹71 Cr | −15.2% | ₹12 Cr | +63.7% | ₹16.85 |
| Q1 FY26 | ₹84 Cr | +2.2% | ₹16 Cr | +145.1% | ₹20.33 |
| Q4 FY25 | ₹82 Cr | +3.4% | ₹0 Cr | −96.1% | ₹1.82 |
| Q3 FY25 | ₹63 Cr | −5.6% | ₹10 Cr | +271.2% | ₹13.41 |
| Q2 FY25 | ₹84 Cr | +18.8% | ₹7 Cr | +198.8% | ₹9.86 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹311 Cr | ₹25 Cr |
| FY24 | ₹305 Cr | ₹17 Cr |
| FY23 | ₹266 Cr | ₹24 Cr |
| FY22 | ₹235 Cr | ₹39 Cr |
| FY21 | ₹214 Cr | ₹35 Cr |
| FY20 | ₹183 Cr | ₹31 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 53.73%
- Foreign institutions: 0.31%
- Domestic institutions: 0.00%
- Non-institutions: 45.95%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Sakar Healthcare](https://app.pivotnow.in/stock/SAKAR) | ₹919.80 | ₹2,047 Cr | 67.3 | — |
| [Syncom Formulations (India)](https://app.pivotnow.in/stock/SYNCOMF) | ₹21.56 | ₹2,027 Cr | 26.6 | — |
| [Beta Drugs](https://app.pivotnow.in/stock/BETA) | ₹1,736.30 | ₹1,925 Cr | 42.5 | — |
| [Fischer Medical Ventures](https://app.pivotnow.in/stock/FISCHER) | ₹28.21 | ₹1,846 Cr | 62.7 | — |
| [Windlas Biotech](https://app.pivotnow.in/stock/WINDLAS) | ₹892.20 | ₹1,841 Cr | 28.6 | — |
| [Titan Biotech](https://app.pivotnow.in/stock/TITANBIO) | — | ₹1,793 Cr | — | — |

## Questions and answers

### What is the share price of Hester Biosciences today?

Hester Biosciences (NSE: HESTERBIO) last closed at ₹2,195.00 on 21 Oct 2026. Its 52-week high is ₹2,683.60 and its 52-week low is ₹1,239.30.

### What is the market cap of Hester Biosciences?

Hester Biosciences' market capitalisation is ₹1,940 Cr (₹1,940 Cr) at the 19 Oct 2026 close, ranking 1170th among the NSE companies Pivot tracks.

### What is the P/E ratio of Hester Biosciences?

Hester Biosciences trades at a trailing P/E of 33.7. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 42.5.

### What is the ROE and ROCE of Hester Biosciences?

Return on equity was 8.7% in FY25 and return on capital employed was 9.1% in FY25 (consolidated figures).

### Is Hester Biosciences a debt-free company?

No. Hester Biosciences' debt-to-equity ratio was 0.66 in FY25, with total debt of ₹133 Cr.

### What were Hester Biosciences' latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Hester Biosciences reported revenue of ₹77 Cr, −8.2% year on year, and net profit of ₹95 Cr, +482.8% year on year.

### How has Hester Biosciences stock performed over the last year?

Hester Biosciences' share price has risen 31.4% over the past year, −8.5% over three months and +0.9% over one month, to the 19 Oct 2026 close.

### What is the shareholding pattern of Hester Biosciences?

As of 30 Jun 2026: promoters 53.73%, foreign institutions 0.31%, domestic institutions 0.00%, non-institutions 45.95%.

### Who are Hester Biosciences' competitors?

The listed Pharma & Healthcare companies closest to Hester Biosciences by market cap are Sakar Healthcare, Syncom Formulations (India), Beta Drugs, Fischer Medical Ventures, Windlas Biotech and Titan Biotech.

### Is Hester Biosciences a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Hester Biosciences' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on HESTERBIO against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.